Texas A&M University
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Texas A&M University
US agency avoided procurement delays with sole-source awards to two medical countermeasures venture partners worth nearly $900m.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
The founders of Rescue Therapeutics Inc. believe they have created a compound that can boost the power of widely used generic cancer drugs, including doxorubicin, without exposing a patient to any additional toxicity. Although RTI’s work with the compound was initially geared to testing it against non-Hodgkin's lymphoma, the start-up is taking it forward as a potential second-line treatment for ovarian cancer.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
- Academic and Research Institutions